GlaxoSmithKline Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
418 result(s) found, displaying 21 to 30
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MENVEO Meningococcal (Groups A,C,W-135 and Y) Oligosaccharide CRM197 solution for injection vial.
-
Apr-2024Prescription medicine evaluationActive ingredient: recombinant respiratory syncytial virus pre-fusion F protein.
-
Apr-2024Prescription medicine evaluationActive ingredient: dostarlimab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZEJULA niraparib (as tosilate monohydrate) 100 mg film-coated tablet blister pack.
-
Prescription medicine decision summaryArexvy (recombinant respiratory syncytial virus pre-fusion F protein) is approved for individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus
-
Prescription medicine registrationActive ingredients: recombinant respiratory syncytial virus pre-fusion F protein.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GlaxoSmithKline Australia Pty Ltd - Medicine chamber spacer.